Stanley, Robert F.
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA242020, 1P50 254838-01)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL128239)
Edward P. Evans Foundation
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (T32-CA009207)
Article History
Received: 10 December 2021
Accepted: 22 April 2022
First Online: 27 May 2022
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine, Inc., Merck, Prelude Therapeutics and Janssen and is on the Scientific Advisory Board of Envisagenics, Inc., AIChemy, Harmonic Discovery, Inc., and Pfizer Boulder. O.A.-W. has received prior research funding from H3B Biomedicine, Nurix Therapeutics and LOXO Oncology unrelated to the current manuscript. The remaining authors declare no competing interests.